Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 14/20 | 0.58 |
| ▸ | AXL | P30530 | 4/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.50 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.50 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13629311 | 0.86 | SLC22A12 (0.62) | SLC22A12AXLHIF1ACYP2C9SLC22A6 | |
| SCHEMBL13852804 | 0.85 | SLC22A12 (0.61) | SLC22A12AXLCYP2C9SLC22A6SLC22A8 | |
| SCHEMBL13629426 | 0.84 | SLC22A12 (0.74) | SLC22A12AXLHIF1ACYP2C9SLC22A6 | |
| SCHEMBL16326028 | 0.83 | SLC22A12 (0.61) | SLC22A12HIF1ACYP2C9SLC22A6SLC22A8 | |
| SCHEMBL13629773 | 0.78 | ALDH1A1 (0.57) | SLC22A12 | |
| SCHEMBL15486381 | 0.78 | SLC22A12 (0.77) | SLC22A12CYP2C9SLC22A6SLC22A8SLC22A11 | |
| SCHEMBL10328530 | 0.77 | AXL (0.73) | AXL | |
| SCHEMBL13853028 | 0.77 | SLC22A12 (0.54) | SLC22A12 | |
| SCHEMBL13615039 | 0.76 | SLC22A12 (0.65) | SLC22A12AXLCYP2C9SLC22A6SLC22A8 | |
| SCHEMBL10328505 | 0.75 | AXL (0.73) | AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118277-A1 | 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | NOVARTIS AG | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118277-A1 | 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | TIE1, TEK, MATK | SLC22A12 4663/4885AXL 98/4885HIF1A 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.